AR124084A1 - ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO - Google Patents
ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATOInfo
- Publication number
- AR124084A1 AR124084A1 ARP210103178A ARP210103178A AR124084A1 AR 124084 A1 AR124084 A1 AR 124084A1 AR P210103178 A ARP210103178 A AR P210103178A AR P210103178 A ARP210103178 A AR P210103178A AR 124084 A1 AR124084 A1 AR 124084A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- folr1
- antibodies
- heavy chain
- folate receptor
- Prior art date
Links
- 229940014144 folate Drugs 0.000 title 1
- 239000011724 folic acid Substances 0.000 title 1
- 102000010451 Folate receptor alpha Human genes 0.000 abstract 6
- 108050001931 Folate receptor alpha Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 abstract 1
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 1
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 1
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 1
- 230000003432 anti-folate effect Effects 0.000 abstract 1
- 229940127074 antifolate Drugs 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 239000004052 folic acid antagonist Substances 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen anticuerpos de cadena pesada del receptor a anti-folato (FOLR1) (por ejemplo, UniAbsTM), junto con métodos para elaborar tales anticuerpos, composiciones, incluidas las composiciones farmacéuticas, que comprenden dichos anticuerpos, y su uso para tratar trastornos que se caracterizan por la expresión del receptor a de folato (FOLR1). Reivindicación 1: Un anticuerpo que se une a FOLR1, el que comprende una primera región variable de cadena pesada que comprende: (a) una secuencia de CDR1 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoácidos de las SEQ ID Nº 1 - 5; y/o (b) una secuencia de CDR2 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoácidos de las SEQ ID Nº 6 - 17; y/o (c) una secuencia de CDR3 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoácidos de las SEQ ID Nº 18 - 22. Reivindicación 46: Una composición farmacéutica que comprende el anticuerpo de una cualquiera de las reivindicaciones 1 a 45. Reivindicación 51: Un polinucleótido que codifica un anticuerpo de cualquiera de las reivindicaciones 1 a 45. Reivindicación 52: Un vector que comprende el polinucleótido de la reivindicación 51. Reivindicación 53: Una célula que comprende el vector de la reivindicación 52. Reivindicación 54: Un método para producir un anticuerpo de cualquiera de las reivindicaciones 1 a 45, el que comprende cultivar una célula de acuerdo con la reivindicación 53 en condiciones permisivas para la expresión del anticuerpo y aislar el anticuerpo de la célula. Reivindicación 55: Un método para elaborar un anticuerpo de cualquiera de las reivindicaciones 1 a 45, el que comprende inmunizar un animal UniRat con una proteína FOLR1 e identificar las secuencias de los anticuerpos que se unen a FOLR1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115436P | 2020-11-18 | 2020-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124084A1 true AR124084A1 (es) | 2023-02-08 |
Family
ID=79024440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103178A AR124084A1 (es) | 2020-11-18 | 2021-11-17 | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240002498A1 (es) |
| EP (1) | EP4247498A1 (es) |
| JP (1) | JP2023549851A (es) |
| KR (1) | KR20230110303A (es) |
| CN (1) | CN116615253A (es) |
| AR (1) | AR124084A1 (es) |
| AU (1) | AU2021383743A1 (es) |
| CA (1) | CA3199785A1 (es) |
| CL (1) | CL2023001432A1 (es) |
| CO (1) | CO2023006790A2 (es) |
| CR (1) | CR20230259A (es) |
| IL (1) | IL302670A (es) |
| MX (1) | MX2023005693A (es) |
| PE (1) | PE20231203A1 (es) |
| TW (1) | TW202233684A (es) |
| UY (1) | UY39522A (es) |
| WO (1) | WO2022109010A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018392088A1 (en) | 2017-12-22 | 2020-08-13 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
| KR20220020810A (ko) | 2019-06-14 | 2022-02-21 | 테네오바이오, 인코포레이티드 | Cd22와 cd3에 결합하는 다중특이적 중쇄 항체 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| US20040110226A1 (en) * | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| AU2003287345A1 (en) | 2002-10-31 | 2004-06-07 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| EP1978032A3 (en) | 2004-07-22 | 2009-02-18 | Erasmus University Medical Center Rotterdam | Binding molecules |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| LT2406284T (lt) | 2009-03-10 | 2016-10-10 | Biogen Ma Inc. | Antikūnai prieš b ląstelių subrendimo antigenus |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20140302037A1 (en) * | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) * | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| JP7146395B2 (ja) * | 2014-11-20 | 2022-10-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | ＦｏｌＲ１及びＣＤ３を標的とする二重特異性抗体 |
| LT3789402T (lt) * | 2014-11-20 | 2022-09-26 | F. Hoffmann-La Roche Ag | Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus |
| MX2018016404A (es) | 2016-06-21 | 2019-10-15 | Teneobio Inc | Anticuerpos de union a cd3. |
| WO2018039180A1 (en) | 2016-08-24 | 2018-03-01 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| RS65595B1 (sr) | 2016-09-14 | 2024-06-28 | Teneoone Inc | Antitela koja vezuju cd3 |
| CA3091683A1 (en) * | 2018-03-13 | 2019-09-19 | Phanes Therapeutics, Inc. | Anti-folate receptor 1 antibodies and uses thereof |
-
2021
- 2021-11-11 TW TW110142033A patent/TW202233684A/zh unknown
- 2021-11-17 AU AU2021383743A patent/AU2021383743A1/en active Pending
- 2021-11-17 IL IL302670A patent/IL302670A/en unknown
- 2021-11-17 CA CA3199785A patent/CA3199785A1/en active Pending
- 2021-11-17 KR KR1020237020120A patent/KR20230110303A/ko unknown
- 2021-11-17 EP EP21824720.3A patent/EP4247498A1/en active Pending
- 2021-11-17 PE PE2023001680A patent/PE20231203A1/es unknown
- 2021-11-17 WO PCT/US2021/059701 patent/WO2022109010A1/en active Application Filing
- 2021-11-17 MX MX2023005693A patent/MX2023005693A/es unknown
- 2021-11-17 CR CR20230259A patent/CR20230259A/es unknown
- 2021-11-17 JP JP2023528641A patent/JP2023549851A/ja active Pending
- 2021-11-17 CN CN202180077625.6A patent/CN116615253A/zh active Pending
- 2021-11-17 US US18/253,197 patent/US20240002498A1/en active Pending
- 2021-11-17 AR ARP210103178A patent/AR124084A1/es unknown
- 2021-11-18 UY UY0001039522A patent/UY39522A/es unknown
-
2023
- 2023-05-18 CL CL2023001432A patent/CL2023001432A1/es unknown
- 2023-05-25 CO CONC2023/0006790A patent/CO2023006790A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023549851A (ja) | 2023-11-29 |
| EP4247498A1 (en) | 2023-09-27 |
| CN116615253A (zh) | 2023-08-18 |
| AU2021383743A1 (en) | 2023-06-08 |
| PE20231203A1 (es) | 2023-08-17 |
| CL2023001432A1 (es) | 2024-01-05 |
| MX2023005693A (es) | 2023-05-29 |
| UY39522A (es) | 2022-06-30 |
| TW202233684A (zh) | 2022-09-01 |
| US20240002498A1 (en) | 2024-01-04 |
| CO2023006790A2 (es) | 2023-06-09 |
| WO2022109010A1 (en) | 2022-05-27 |
| CR20230259A (es) | 2023-07-13 |
| KR20230110303A (ko) | 2023-07-21 |
| IL302670A (en) | 2023-07-01 |
| CA3199785A1 (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR126242A2 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
| PE20181044A1 (es) | Anticuerpos anti-pd-1 y composiciones | |
| PE20220278A1 (es) | Dominios variables de anticuerpos que se dirigen al receptor nkg2d | |
| AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
| BR112017019978A2 (pt) | anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo | |
| AR108066A1 (es) | Receptores quiméricos para cll-1 y métodos de uso de los mismos | |
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
| JP2016536322A5 (es) | ||
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| PE20220575A1 (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3 | |
| PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| PE20181956A1 (es) | Polipeptidos que inhiben cd40l | |
| AR101202A1 (es) | Anticuerpo anti-tie2 humana | |
| AR115419A1 (es) | Anticuerpos anti-tmeff2 monoespecíficos y multiespecifícos y sus usos | |
| PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
| PE20240761A1 (es) | Proteinas de union a psma y usos de estas |